Makes traditional Chinese medicine products aimed at older adults and distributes other companies’ medicines and health products to pharmaceutical distributors, healthcare providers and drugstore chains.
20-F for FY2025, filed Jan 29, 2026Through the PRC operating entities, we are a pharmaceutical company based in Jiangxi, China, specializing in the manufacturing, marketing…View ↗
The PRC operating entities’ third-party products. Through our subsidiary, Universe Trade, we also distribute and sell products manufactured…View ↗
The PRC operating entities’ Customers. The PRC operating entities’ major customers are pharmaceutical distributors, hospitals, clinics and…View ↗
Customers pay for company-made and third-party products when they are delivered and accepted; sales may also be made on credit.
20-F for FY2025, filed Jan 29, 2026Revenue from sales of TCMD products and third-party products is recognized when the products are delivered to customers. Each customer…View ↗
20-F for FY2025, filed Jan 29, 2026
FY2025 revenue by product or service ↗$17.9B
20-F for FY2025, filed Jan 29, 2026
$17.9B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Revenue from sales of self-manufactured TCMD products
Sold outright
20-F for FY2025, filed Jan 29, 2026 |
74% |
Revenue from sales of self-manufactured TCMD products, FY2025
$13.3B Sources
|
Sold outright |
|
Revenue from sales of third-party products
Sold outright
20-F for FY2025, filed Jan 29, 2026 |
26% |
Revenue from sales of third-party products, FY2025
$4.6B Sources
|
Sold outright |
Sells to pharmaceutical distributors, hospitals, clinics and drugstore chains, which are authorized to sell and deliver products to end consumers.
20-F for FY2025, filed Jan 29, 2026Our customers are mostly pharmaceutical distributors, hospitals, clinics and drugstore chains with pharmaceutical business qualification…View ↗
No. It lost $3.7B in FY2025.
20-F for FY2025, filed Jan 29, 2026
−$2.9BView ↗
20-F for FY2025, filed Jan 29, 2026
−$3.7BView ↗
20-F for FY2025, filed Jan 29, 2026
−$5.3BView ↗
Growing. Revenue grew 372.2x in 4 years, from $48M in FY2021 to $17.9B in FY2025, about 339% a year.
Loading...